Objective To explore the clinical efficacy of Calcipotriol combined with Acitretin Capsules in the treatment of common psoriasis vulgaris.Methods A total of 80 patients with common psoriasis vulgaris who were admitted to Guangdong Qingyuan Prevention and Treatment Hospital of Chronic Disease from January 2019 to October 2020 were selected.They were divided into two groups by random number table method,with 40 cases in each group.The control group was treated with Acitretin Capsules,and the study group was given Acitretin Capsules combined with Calcipotriol for treatment.All groups were treated for 30 days.The inflammatory factors(tumor necrosis factor-α [TNF-α],interleukin[IL]-23,IL-17),vascular endothelial growth factor(VEGF)levels,psoriasis lesion area and severity index(PASI)scores of patients in both groups before and after treatment were observed and compared,and the treatment effect were compared between the two groups.Results After treatment,TNF-α in study group was (94.23±1.08)μg/L,IL-23 in study group was(184.31±9.16)μg/L,IL-17 in study group was(92.16±6.63)μg/L,which were lower than those in the control group of(105.17±8.32),(207.41±10.69),(103.41±7.69)μg/L,the differences were statistically significant(P＜0.05).After treatment,VEGF level in study group was(93.55±9.14)ng/ml,and PASI score in study group was(5.14±1.05)points,which were lower than those in control group of(114.30±10.80)ng/ml and(7.30±1.26)points,the differences were statistically significant(P＜0.05).The total effective rate in study group(97.5%)was higher than that in control group(70.0%),and the difference was statistically significant(P＜0.05).Conclusion Compared with Acitretin Capsules alone in the treatment of common psoriasis vulgaris,the combined application of Calcipotriol combined with Acitretin Capsules is more effective.It can improve the body′s inflammatory factor levels,reduce the PASI scores and VEGF levels,improve the treatment effect,and help improve the patient′s prognosis and quality of life.